Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC

NCT03711422 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped Decision to close the trial made due to low recruitment.

Conditions

Non-small Cell Lung Cancer
Leptomeningeal Disease
Central Nervous System Metastases

Interventions

DRUG: Afatinib
DRUG: Afatinib

Sponsor

National Cancer Centre, Singapore